Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus SOX in locally advanced esophagogastric junction adenocarcinoma
NCT05170503Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in esophagogastric junction adenocarcinoma (GEJA), sponsored by Sun Yat-sen University. Started Dec 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05170503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170503.